Clinical trials: Refractory Solid Tumors
Refractory Solid Tumors, Cancer Tumor
An Open-Label, Dose-Escalation Study of AZD2461
This study is being conducted to test study drug AZD2461 to see how it may work to treat solid tumors. The main purpose of this study is to determine the safety and tolerability of AZD2461.
- Trial name
- NCT01247168
- Testing
- AZD2461
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Refractory Cancer, Recurrent Cancer
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A*02 eligible patients with…
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- Trial name
- NCT06372574
- Testing
- RO7617991, Tocilizumab
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
- Trial name
- NCT07524348
- Testing
- E303
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 149 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Advanced Solid Tumor, Relapsed AML
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia
This is an early phase clinical study using NEI-01 as single agent in oncology indication. This is an open label study and it's divided into two parts.
- Conditions
- Advanced Solid Tumor, Relapsed AML, Refractory AML
- Trial name
- NCT05226468
- Testing
- NEI-01
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- New Epsilon Innovation Limited
Melanoma, Solid Tumor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of…
- Conditions
- Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer
- Trial name
- NCT07121829
- Testing
- Tovorafenib, Tovorafenib Drug: Pimasertib
- Where
- 10 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Ewing Sarcoma, Solid Tumors
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults…
- Conditions
- Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma
- Trial name
- NCT03709680
- Testing
- Palbociclib, Temozolomide, Irinotecan
- Where
- 84 sites in United States, Brazil and 11 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Solid Tumor, Adult, Refractory Tumor
A Study of DCR-STAT3 in Adults With Solid Tumors
This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.
- Trial name
- NCT06098651
- Testing
- DCR-STAT3
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Adenocarcinoma, Neoplasms
Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
This is an open label, two-part study of temsirolimus given as a 60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors.
- Trial name
- NCT00106353
- Testing
- Torisel
- Where
- 30 sites in United States, Canada and 5 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Advanced Malignancy, Advanced Solid Tumors
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
- Trial name
- SDX-0101 (NCT02743637)
- Testing
- SDX-7320
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- SynDevRx, Inc.
Refractory Cancer, Recurrent Cancer
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
The goal of this clinical trial is to evaluate the safety, tolerability and initial anti-tumor activity of IMA401 as monotherapy or in combination with checkpoint inhibitor in patients with recurrent and/or refractory solid…
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
- Trial name
- NCT05359445
- Testing
- IMA401 (Phase Ia), Pembrolizumab (Phase Ia), IMA 401 (Phase Ib)
- Where
- 21 sites in Germany
- Volunteers
- 95 people
- Sponsor
- Immatics Biotechnologies GmbH
Solid Tumors
Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors
This is a Phase 1, dose escalation study evaluating safety and pharmacokinetics of enteric coated D-3263 HCl in subjects with advanced solid tumors
- Trial name
- NCT00839631
- Testing
- EC D-3263 HCl
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dendreon
Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT04721015
- Testing
- ABBV-637, Docetaxel, Osimertinib
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 81 people
- Sponsor
- AbbVie
Solid Tumor, Adult, Relapsed Cancer
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of…
- Conditions
- Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05662397
- Testing
- HST-1011, Cemiplimab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 77 people
- Sponsor
- HotSpot Therapeutics, Inc
Neoplasms
First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors
An open-label, non-randomized, Phase I dose-escalation study designed to assess the safety, tolerability, pharmacokinetics(PK) /pharmacodynamics( PD) and tumor response profile of BAY1179470 in subjects with advanced, refractory…
- Trial name
- NCT01881217
- Testing
- BAY1179470
- Where
- 8 sites in Japan, Singapore and 1 more
- Volunteers
- 35 people
- Sponsor
- Bayer
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Refractory Solid Tumours, Relapsed Small Cell Lung Cancer (SCLC)
AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors
The purpose of this Phase 1b, multi-centre, dose escalation study is to find the maximum tolerated dose (MTD) of AZD1775 combined with olaparib in patients with refractory solid tumours
- Trial name
- NCT02511795
- Testing
- AZD1775, Olaparib
- Where
- 6 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Neoplasms
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
This study will evaluate the combination of a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, niraparib, with the programmed cell death protein 1 (PD-1) inhibitor, dostarlimab in the paediatric population.
- Trial name
- NCT04544995
- Testing
- Niraparib (Tablet for oral suspension), Dostarlimab, Niraparib (Tablet)
- Where
- 2 sites in United Kingdom
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Solid Tumors Refractory To Standard Therapy, Neoplasms
Kanglaite Injection Phase I Study
The Kanglaite Injection (KLT)is a novel broad spectrum anti-cancer injection produced from traditional Chinese medicinal herbs (the Coix Seed).
- Trial name
- NCT00031031
- Testing
- Kanglaite Injection (KLT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- KangLaiTe USA
Recurrent Glioma, Solid Tumor
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT)…
- Trial name
- NCT04794972
- Testing
- GNC-039
- Where
- 6 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Cancer, Malignancy
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
CAR-T is a pioneering cancer treatment which has found success in some cancers. This treatment is made first by taking blood cells from the patient.
- Conditions
- Cancer, Malignancy, Refractory Cancer, Relapsed Cancer
- Trial name
- ANGELICA (NCT05302037)
- Testing
- Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
- Where
- Singapore
- Volunteers
- 12 people
- Sponsor
- CytoMed Therapeutics Pte Ltd